SEC Form 25-NSE filed by Kronos Bio Inc.

6/20/25 11:35:18 AM ET

$KRON

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KRON alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-248925

Issuer:	Kronos Bio, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1300 So. El Camino Real, Suite 300
	San Mateo	CALIFORNIA	94402
Telephone number:				650-781-5200

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-06-20	By	Tara Petta		AVP
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $KRON alert in real time by email

Recent Analyst Ratings for

$KRON

Date	Price Target	Rating	Analyst
11/14/2024	$6.00 → $1.00	Overweight → Neutral	Piper Sandler
11/14/2024		Buy → Hold	TD Cowen
9/14/2022	$12.00	Buy	Berenberg
2/28/2022	$50.00 → $30.00	Overweight	Piper Sandler
11/10/2021	$35.00 → $36.00	Buy	HC Wainwright & Co.
10/20/2021		Outperform	Cowen
6/24/2021	$35.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form 25-NSE filed by Kronos Bio Inc.

6/20/25 11:35:18 AM ET

$KRON

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KRON alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-248925

Issuer:	Kronos Bio, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1300 So. El Camino Real, Suite 300
	San Mateo	CALIFORNIA	94402
Telephone number:				650-781-5200

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

2025-06-20	By	Tara Petta		AVP
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $KRON alert in real time by email

Recent Analyst Ratings for

$KRON

Date	Price Target	Rating	Analyst
11/14/2024	$6.00 → $1.00	Overweight → Neutral	Piper Sandler
11/14/2024		Buy → Hold	TD Cowen
9/14/2022	$12.00	Buy	Berenberg
2/28/2022	$50.00 → $30.00	Overweight	Piper Sandler
11/10/2021	$35.00 → $36.00	Buy	HC Wainwright & Co.
10/20/2021		Outperform	Cowen
6/24/2021	$35.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form 25-NSE filed by Kronos Bio Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $KRON

SEC Form 25-NSE filed by Kronos Bio Inc.

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $KRON

$KRON Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Bischofberger Norbert W

SEC Form 4 filed by Director Belldegrun Arie

Director Ridloff Elena closing all direct ownership in the company (SEC Form 4)

$KRON SEC Filings

SEC Form 15-12G filed by Kronos Bio Inc.

SEC Form EFFECT filed by Kronos Bio Inc.

SEC Form S-8 POS filed by Kronos Bio Inc.

$KRON Press Releases

Fastest customizable press release news feed in the world

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Kronos Bio Announces CEO Transition and Reduction in Force

$KRON Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Kronos downgraded by Piper Sandler with a new price target

Kronos downgraded by TD Cowen

Berenberg initiated coverage on Kronos with a new price target

$KRON Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

PRESIDENT & CEO Bischofberger Norbert W bought $3,119,081 worth of shares (3,005,122 units at $1.04) (SEC Form 4)

Bischofberger Norbert W bought $1,470,395 worth of shares (1,731,056 units at $0.85), increasing direct ownership by 214% to 2,540,665 units (SEC Form 4)

$KRON Leadership Updates

Live Leadership Updates

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

Vicore Expands and Strengthens its Board of Directors

$KRON Financials

Live finance-specific insights

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

$KRON Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Kronos Bio Inc.

Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

Recent Analyst Ratings for
$KRON

Recent Analyst Ratings for
$KRON

$KRON
Insider Trading

$KRON
SEC Filings

$KRON
Press Releases

$KRON
Analyst Ratings

$KRON
Insider Purchases

$KRON
Leadership Updates

$KRON
Financials

$KRON
Large Ownership Changes